SCHEMBL3011395

SCHEMBL3011395

Cc1cccc(Cc2csc(N3CCN(S(=O)(=O)c4cc(Cl)ccc4Cl)CC3)n2)c1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.49
ALDH3A1 P30838 1/20 0.49
MAPT P10636 2/20 0.43
TDP1 Q9NUW8 1/20 0.41
ALOX15 P16050 1/20 0.41
TSHR P16473 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
KDM4E B2RXH2 1/20 0.40
POLB P06746 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
USP2 O75604 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
KDM2B Q8NHM5 1/20 0.39
TRPV4 Q9HBA0 1/20 0.39
RECQL P46063 1/20 0.38
LMNA P02545 1/20 0.38
CNR1 P21554 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3008696 0.93 TRPV4 (0.47) ALDH1A1ALDH3A1MAPTKDM4EPOLB
SCHEMBL3006655 0.92 MAPT (0.45) ALDH1A1ALDH3A1MAPTTDP1ALOX15
SCHEMBL3010327 0.91 MEN1 (0.43) ALDH1A1MAPTKDM4EPOLBSMN1; SMN2
SCHEMBL3003251 0.90 ALDH1A1 (0.48) ALDH1A1MAPTTDP1TSHRKDM4E
SCHEMBL3019609 0.90 MAPT (0.45) ALDH1A1ALDH3A1MAPTTDP1ALOX15
SCHEMBL3023185 0.89 TRPV4 (0.47) ALDH1A1MAPTTDP1ALOX15TSHR
SCHEMBL3015793 0.89 ALDH1A1 (0.42) ALDH1A1ALDH3A1MAPTTDP1ALOX15
SCHEMBL3019075 0.89 TP53 (0.42) ALDH1A1ALDH3A1MAPTL3MBTL1KDM4E
SCHEMBL3010619 0.89 NPSR1 (0.46) ALDH1A1MAPTTSHRL3MBTL1KDM4E
SCHEMBL3002593 0.89 MEN1 (0.46) ALDH1A1ALDH3A1MAPTTSHRL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885ALDH3A1 3980/4885MAPT 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.